Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)
Piper Sandler's Edward Tenthoff reiterated a Buy rating on NextCure (NXTC) with a $15.00 price target. Tenthoff, who covers the Healthcare sector, has an average return of -8.8% and a 33.95% success rate. The analyst consensus on NextCure is a Moderate Buy with an average price target of $19.00.
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on NextCure, with a price target of $15.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Tenthoff is an analyst with an average return of -8.8% and a 33.95% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arvinas Holding Company, and Moderna.
Currently, the analyst consensus on NextCure is a Moderate Buy with an average price target of $19.00.
